A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis (ELIVATE).

drug protocol number
CLJN452D12201C
drug sponsor
Novartis
drug study
LJN452
drug trial site
King Fahad Medical City (Riyadh)
drug status
Ongoing
drug phase